Ratio of Visceral to Subcutaneous Fat Area Is a Biomarker of Complicated Crohns Disease
Clinical Gastroenterology and Hepatology , 08/15/2011

1 Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate Helicobacter, April 6, 2012    Clinical Article

2 Adalimumab in steroid-dependent Crohns disease patients: Prognostic factors for clinical benefit Inflammatory Bowel Disease, April 17, 2012    Clinical Article

3 Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohns Disease Gastroenterology, February 29, 2012    Clinical Article

4 Serrated Polyp Detection Rate During Screening Colonoscopy Colorectal Disease, March 14, 2012

5 High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures Alimentary Pharmacology and Therapeutics, March 12, 2012    Clinical Article

6 Natalizumab for moderate to severe Crohns disease in clinical practice Inflammatory Bowel Disease, April 3, 2012    Clinical Article

7 Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease Inflammatory Bowel Disease, April 23, 2012    Clinical Article

8 Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals Gastroenterology, April 6, 2012

9 Randomized Comparison of Two Non-Bismuth-Containing Second-line Rescue Therapies for Helicobacter pylori Helicobacter, April 11, 2012    Clinical Article

10 Natalizumab for moderate to severe Crohns disease in clinical practice Inflammatory Bowel Disease, April 18, 2012    Clinical Article

11 Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains Helicobacter, April 13, 2012    Clinical Article

12 Scheduled infliximab monotherapy to prevent recurrence of Crohns disease following ileocolic or ileal resection: A 3-year prospective randomized open trial Inflammatory Bowel Disease, April 20, 2012    Clinical Article

13 Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease Inflammatory Bowel Disease, April 16, 2012    Clinical Article

14 Assessment of Helicobacter pylori Eradication by Virgin Olive Oil Helicobacter, April 24, 2012    Clinical Article

15 Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing Diseases of the Esophagus, April 27, 2012    Clinical Article

16 Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study Hepatology, April 19, 2012    Clinical Article

17 Systematic review: antibodies and anti-TNF- levels in inflammatory bowel disease Alimentary Pharmacology and Therapeutics, April 12, 2012    Clinical Article

18 Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis Journal of Digestive Diseases, March 27, 2012    Evidence Based Medicine    Clinical Article

19 Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial The Lancet Infectious Diseases, March 27, 2012    Clinical Article

20 The Association Between Barretts Esophagus and Helicobacter pylori Infection: A Meta-Analysis Helicobacter, April 3, 2012    Clinical Article